Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains
- PMID: 23165468
- PMCID: PMC3553693
- DOI: 10.1128/AAC.01696-12
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains
Abstract
Avermectins are a family of macrolides known for their anthelmintic activities and traditionally believed to be inactive against all bacteria. Here we report that members of the family, ivermectin, selamectin, and moxidectin, are bactericidal against mycobacterial species, including multidrug-resistant and extensively drug-resistant clinical strains of Mycobacterium tuberculosis. Avermectins are approved for clinical and veterinary uses and have documented pharmacokinetic and safety profiles. We suggest that avermectins could be repurposed for tuberculosis treatment.
Figures



Similar articles
-
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme.Int J Mol Sci. 2022 Jan 11;23(2):771. doi: 10.3390/ijms23020771. Int J Mol Sci. 2022. PMID: 35054958 Free PMC article.
-
Avermectins and milbemycins.J Vet Pharmacol Ther. 1996 Oct;19(5):331-51. doi: 10.1111/j.1365-2885.1996.tb00062.x. J Vet Pharmacol Ther. 1996. PMID: 8905567 Review. No abstract available.
-
Selection at a gamma-aminobutyric acid receptor gene in Haemonchus contortus resistant to avermectins/milbemycins.Mol Biochem Parasitol. 2003 Oct;131(2):137-45. doi: 10.1016/s0166-6851(03)00201-9. Mol Biochem Parasitol. 2003. PMID: 14511812
-
Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates.Antimicrob Agents Chemother. 2012 Aug;56(8):4140-5. doi: 10.1128/AAC.06445-11. Epub 2012 May 21. Antimicrob Agents Chemother. 2012. PMID: 22615274 Free PMC article.
-
Avermectin/milbemycin resistance in trichostrongyloid nematodes.Int J Parasitol. 1998 Jun;28(6):863-77. doi: 10.1016/s0020-7519(98)00068-x. Int J Parasitol. 1998. PMID: 9673866 Review.
Cited by
-
Anthelmintic Therapy Modifies the Systemic and Mycobacterial Antigen-Stimulated Cytokine Profile in Helminth-Latent Mycobacterium tuberculosis Coinfection.Infect Immun. 2017 Mar 23;85(4):e00973-16. doi: 10.1128/IAI.00973-16. Print 2017 Apr. Infect Immun. 2017. PMID: 28167672 Free PMC article.
-
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.Life (Basel). 2022 Sep 6;12(9):1384. doi: 10.3390/life12091384. Life (Basel). 2022. PMID: 36143420 Free PMC article. Review.
-
Repurposing clinically approved cephalosporins for tuberculosis therapy.Sci Rep. 2016 Sep 28;6:34293. doi: 10.1038/srep34293. Sci Rep. 2016. PMID: 27678056 Free PMC article.
-
Innovative Strategies in Drug Repurposing to Tackle Intracellular Bacterial Pathogens.Antibiotics (Basel). 2024 Sep 2;13(9):834. doi: 10.3390/antibiotics13090834. Antibiotics (Basel). 2024. PMID: 39335008 Free PMC article. Review.
-
Mycobacterium susceptibility to ivermectin by inhibition of eccD3, an ESX-3 secretion system component.PLoS Comput Biol. 2025 Apr 17;21(4):e1012936. doi: 10.1371/journal.pcbi.1012936. eCollection 2025 Apr. PLoS Comput Biol. 2025. PMID: 40245093 Free PMC article.
References
-
- Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29–40 - PubMed
-
- Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. 2011. The challenge of new drug discovery for tuberculosis. Nature 469:483–490 - PubMed
-
- Chong CR, Sullivan DJ., Jr 2007. New uses for old drugs. Nature 448:645–646 - PubMed
-
- Omura S, Crump A. 2004. The life and times of ivermectin—a success story. Nat. Rev. Microbiol. 2:984–989 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases